Pharmacotherapy of mild cognitive impairment
Amnestic mild cognitive impairment (MCI) can be considered as a state with a high risk of developing Alzheimer's disease within 5 years, or as a prodromal stage of this condition. Randomized clinical trials comparing the acetylcholinesterase inhibitor donepezil with placebo have shown some symp...
| Main Author: | |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Les Laboratoires Servier
2004
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3181817/ |